title: ÐÐ¸Ð¾ÑÐ°ÑÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ Ð¸ Ð´Ð¾Ð·Ð¸Ð¼ÐµÑÑÐ¸Ñ Ð°Ð½ÑÐ°Ð³Ð¾Ð½Ð¸ÑÑÐ° ÑÐ¾Ð¼Ð°ÑÐ¾ÑÑÐ°ÑÐ¸Ð½Ð¾Ð²ÑÑ ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ¾Ð² 2 ÑÐ¸Ð¿Ð° JR-11, Ð¼ÐµÑÐµÐ½Ð½Ð¾Ð³Ð¾ 68Ga Ð¸ 177Lu, Ð´Ð»Ñ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÐ¸ Ð¸ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ð½ÐµÐ¹ÑÐ¾ÑÐ½Ð´Ð¾ÐºÑÐ¸Ð½Ð½ÑÑ Ð¾Ð¿ÑÑ Ð¾Ð»ÐµÐ¹
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Biodistribution and dosimetry of the 68Ga and 177Lu labeled JR-11 type 2 somatostatin receptor antagonist for the diagnosis and therapy of neuroendocrine tumors
Creators: name: ÐÑÑÐ½Ð°ÑÐµÐ½ÐºÐ¾, Ð¡ÑÐ°Ð½Ð¸ÑÐ»Ð°Ð²
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2021
Subjects: ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð°Ñ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÐ°
ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð°Ñ ÑÐµÑÐ°Ð¿Ð¸Ñ
Ð°Ð½ÑÐ°Ð³Ð¾Ð½Ð¸ÑÑ ÑÐ¾Ð¼Ð°ÑÐ¾ÑÑÐ°ÑÐ¸Ð½Ð¾Ð²ÑÑ ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ¾Ð² 2 ÑÐ¸Ð¿Ð° jr-11
Ð¾Ð¿ÑÑ Ð¾Ð»Ñ
Ð±Ð¸Ð¾ÑÐ°ÑÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ ÑÐ°Ð´Ð¸Ð¾ÑÐ°ÑÐ¼Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÐ¾Ð²
Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÐµ Ð´Ð¾Ð·Ñ
radionuclide diagnostics
radionuclide therapy
somatostatin receptor antagonist type 2 jr-11
tumor
biodistribution of radiopharmaceuticals
absorbed doses

description: ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ Ð±Ð¸Ð¾ÑÐ°ÑÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ñ Ð°Ð½ÑÐ°Ð³Ð¾Ð½Ð¸ÑÑÐ° ÑÐ¾Ð¼Ð°ÑÐ¾ÑÑÐ°ÑÐ¸Ð½Ð¾Ð²ÑÑ ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ¾Ð² 2 ÑÐ¸Ð¿Ð°, Ð¼ÐµÑÐµÐ½Ð½Ð¾Ð³Ð¾ 68Ga Ð¸ 177Lu Ñ Ð´Ð°Ð»ÑÐ½ÐµÐ¹ÑÐµÐ¹ ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐºÐ¾Ð¹ Ð¼ÐµÑÐ¾Ð´Ð¾Ð² Ð¾ÑÐµÐ½ÐºÐ¸ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÑ Ð´Ð¾Ð·. ÐÐ°Ð´Ð°ÑÐ¸, ÐºÐ¾ÑÐ¾ÑÑÐµ ÑÐµÑÐ°Ð»Ð¸ÑÑ Ð² ÑÐ¾Ð´Ðµ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ: 1. ÐÐ·ÑÑÐµÐ½Ð¸Ðµ Ð»Ð¸ÑÐµÑÐ°ÑÑÑÑ Ð¿Ð¾ Ð±Ð¸Ð¾ÑÐ°ÑÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ñ Ð¸ Ð´Ð¾Ð·Ð¸Ð¼ÐµÑÑÐ¸Ð¸ Ð°Ð½ÑÐ°Ð³Ð¾Ð½Ð¸ÑÑÐ° ÑÐ¾Ð¼Ð°ÑÐ¾ÑÑÐ°ÑÐ¸Ð½Ð¾Ð²ÑÑ ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ¾Ð² 2 ÑÐ¸Ð¿Ð° JR-11, Ð¼ÐµÑÐµÐ½Ð½Ð¾Ð³Ð¾ 68Ga Ð¸ 177Lu, Ð´Ð»Ñ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÐ¸ Ð¸ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ð½ÐµÐ¹ÑÐ¾ÑÐ½Ð´Ð¾ÐºÑÐ¸Ð½Ð½ÑÑ Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ¹. 2. ÐÐ¾ÑÑÑÐ¾ÐµÐ½Ð¸Ðµ ÐºÑÐ¸Ð²ÑÑ Ð²ÑÐ²ÐµÐ´ÐµÐ½Ð¸Ñ-Ð½Ð°ÐºÐ¾Ð¿Ð»ÐµÐ½Ð¸Ñ Ð Ð¤Ð Ð´Ð»Ñ ÑÐ°Ð·Ð½ÑÑ Ð¾ÑÐ³Ð°Ð½Ð¾Ð² Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ð°Ð½Ð¸Ð¸ Ð´Ð°Ð½Ð½ÑÑ Ð¸Ð· Ð»Ð¸ÑÐµÑÐ°ÑÑÑÐ½Ð¾Ð³Ð¾ Ð¾Ð±Ð·Ð¾ÑÐ°. 3. Ð Ð°ÑÑÑÑ Ð¸Ð½ÑÐµÐ³ÑÐ°Ð»ÑÐ½Ð¾Ð¹ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ Ð¸ Ð¾Ð¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÑ Ð´Ð¾Ð·. 4. ÐÐ½Ð°Ð»Ð¸Ð· Ð¿Ð¾Ð»ÑÑÐµÐ½Ð½ÑÑ Ð´Ð¾Ð·. Ð Ð°Ð±Ð¾ÑÐ° Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½Ð° Ð½Ð° Ð±Ð°Ð·Ðµ Ð»Ð°Ð±Ð¾ÑÐ°ÑÐ¾ÑÐ¸Ð¸ ÑÐ°Ð´Ð¸Ð°ÑÐ¸Ð¾Ð½Ð½Ð¾Ð¹ Ð³Ð¸Ð³Ð¸ÐµÐ½Ñ Ð¼ÐµÐ´Ð¸ÑÐ¸Ð½ÑÐºÐ¸Ñ Ð¾ÑÐ³Ð°Ð½Ð¸Ð·Ð°ÑÐ¸Ð¹ Ð¤ÐÐ£Ð ÐÐÐÐ Ð Ð¸Ð¼. Ð.Ð. Ð Ð°Ð¼Ð·Ð°ÐµÐ²Ð°. ÐÑÐ»Ð¸ Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½Ñ ÑÐ°ÑÑÑÑÑ Ð¿Ð¾Ð³Ð»Ð¾ÑÑÐ½Ð½ÑÑ Ð´Ð¾Ð· Ð² Ð¾ÑÐ³Ð°Ð½Ð°Ñ. ÐÑÐ°ÑÐ¸ÐºÐ¸ ÑÑÑÐ¾Ð¸Ð»Ð¸ÑÑ Ð¸ Ð¾Ð±ÑÐ°Ð±Ð°ÑÑÐ²Ð°Ð»Ð¸ÑÑ Ð¿ÑÐ¸ Ð¿Ð¾Ð¼Ð¾ÑÐ¸ Origin Lab Ð¸ MS Excel. ÐÐ½Ð°Ð»Ð¸Ð· Ð¿ÑÐ¾Ð¸Ð·Ð²Ð¾Ð´Ð¸Ð»ÑÑ Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ðµ ÑÑÐ°Ð½Ð´Ð°ÑÑÐ½Ð¾Ð³Ð¾ Ð¾ÑÐºÐ»Ð¾Ð½ÐµÐ½Ð¸Ñ. Ð ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐµ Ð±ÑÐ»Ð¸ Ð¿ÑÐ¾Ð°Ð½Ð°Ð»Ð¸Ð·Ð¸ÑÐ¾Ð²Ð°Ð½Ñ Ð´Ð°Ð½Ð½ÑÐµ Ð¾Ð± Ð°Ð½ÑÐ°Ð³Ð¾Ð½Ð¸ÑÑÐµ ÑÐ¾Ð¼Ð°ÑÐ¾ÑÑÐ°ÑÐ¸Ð½Ð¾Ð²ÑÑ ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ¾Ð² 2 ÑÐ¸Ð¿Ð°, Ð¾ÑÐµÐ½ÐµÐ½Ñ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÐµ Ð´Ð¾Ð·Ñ Ð² Ð¾ÑÐ³Ð°Ð½Ð°Ñ Ð¸ ÑÐ´ÐµÐ»Ð°Ð½Ñ Ð²ÑÐ²Ð¾Ð´Ñ Ð¾ Ð¿ÑÐ¸Ð¼ÐµÐ½Ð¸Ð¼Ð¾ÑÑÑ ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐ°Ð½Ð½Ð¾Ð³Ð¾ Ð½Ð°Ð¼Ð¸ Ð¿Ð¾Ð´ÑÐ¾Ð´Ð° Ðº Ð´Ð¾Ð·Ð¸Ð¼ÐµÑÑÐ¸Ð¸ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð², Ð¿ÑÐ¾ÑÐ¾Ð´ÑÑÐ¸Ñ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÑ.
description: This work is devoted to the study of the bio-distribution of the type 2 somatostatin receptor antagonist labeled 68Ga and 177Lu, with further development of methods for assessing absorbed doses. Tasks that were solved in the course of the study: 1. Study of the literature on the biodistribution and dosimetry of the type 2 somatostatin receptor antagonist JR-11, labeled 68Ga and 177Lu, for the diagnosis and therapy of neuroendocrine tumors. 2. Construction of the RPF elimination-accumulation curves for different organs based on the data from the literature review. 3. Calculation of the integral activity and determination of absorbed doses. 4. Analysis of the received doses. The work was carried out on the basis of the laboratory of radiation hygiene of medical organizations of the P. V. Ramzaev Federal State Medical University. Calculations were performed to show which organs had the highest radionuclide content and the absorbed dose in the organs. The graphs were built and processed using Origin Lab and MS Excel. The analysis was based on the standard deviation. As a result, data on the antagonist of somatostatin receptors of type 2 were analyzed, the absorbed doses in the organs were evaluated, and conclusions were made about the applicability of the approach developed by us to dosimetry of patients undergoing diagnosis.